Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and ...

If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite ...

Within Pfizer’s large product portfolio, several mixed product trends led to overall 4% year-over-year growth, with particularly strong sales in vaccines and cancer drugs offsetting declines from ...

Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago. Pfizer made ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. The oncology business shows promising growth, particularly with products like ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of the struggling pharmaceuticals giant, according to a person familiar with ...

ALEXANDRIA, VA (June 17, 1999)-- Pfizer (NYSE: PFE) is trading at 38 times its trailing 12-month earnings per share, 40 times 1999 estimates, and 33.9 times the year 2000 EPS guess. The largest ...